Introduction to De Novo Sequencing

De novo sequencing stands as a fundamental pillar in biological research, enabling the elucidation of primary sequence information for nucleic acids (DNA/RNA) and proteins directly from experimental data, without the guidance of a known reference sequence. This approach is paramount when studying novel organisms, uncharacterized proteins, or systems where reference genomes are unavailable, incomplete, or significantly divergent.

What is De Novo Sequencing?

The term "de novo" is Latin for "from the new" or "from the beginning." In the context of molecular biology, de novo sequencing refers to the process of determining the precise order of nucleotides in a DNA or RNA molecule, or the amino acid sequence in a protein, without any prior knowledge of the sequence. It is akin to piecing together a complex puzzle without the final picture on the box. This contrasts sharply with re-sequencing or reference-based approaches, which map sequence reads to an existing template.

For nucleic acids, this involves fragmenting the DNA or RNA, sequencing these smaller pieces, and then computationally assembling them into a contiguous sequence (contig) or a complete genome/transcriptome. For proteins, it typically involves digesting the protein into peptides, analyzing these peptides by mass spectrometry, and inferring the peptide sequences from their fragmentation patterns, which are then ordered to reconstruct the protein sequence.

Key Principles and Goals

The core principle of de novo sequencing, whether for nucleic acids or proteins, revolves around a few key stages:

• Fragmentation: The large biomolecule (DNA, RNA, or protein) is broken down into smaller, manageable fragments.
• Sequencing/Analysis of Fragments: Each fragment is then "read" to determine its sequence.

• For DNA/RNA, this involves Next-Generation Sequencing (NGS) or Third-Generation Sequencing (TGS) platforms that generate millions of sequence reads.
• For proteins/peptides, this involves mass spectrometry (MS), particularly tandem mass spectrometry (MS/MS), to determine mass-to-charge ratios (m/z) of peptide fragments, from which amino acid sequences can be inferred.

• Assembly/Interpretation: Sophisticated bioinformatics algorithms are used to find overlapping sequences among the fragments and piece them together, reconstructing the original full-length sequence. For peptides, this involves deducing the amino acid sequence from spectral data.

The primary goals of de novo sequencing include:

• Discovery: Unveiling the genetic makeup of novel organisms or the structure of unknown proteins.
• Characterization: Providing a foundational blueprint for unstudied species or biomolecules.
• Comparative Analysis: Enabling evolutionary studies by comparing newly sequenced genomes/proteins with known ones.
• Functional Annotation: Identifying genes, regulatory regions, protein domains, and potential functions.
• Completing Gaps: Filling in missing regions in existing reference genomes.
• Understanding Variation: Identifying structural variants, novel splice isoforms, or unique protein modifications not present in databases.

De Novo Sequencing vs. Reference-Based Sequencing

Understanding the distinction between de novo and reference-based sequencing is crucial for selecting the appropriate strategy for a given research objective.

At Creative Biolabs, we provide expert consultation to help you determine the most effective sequencing strategy tailored to your research needs and the nature of your biological samples.

De Novo Genomics Sequencing

De Novo Genome Sequencing

This involves assembling the complete genome sequence of an organism for the first time. It is indispensable for:

• Characterizing newly discovered species: From bacteria and viruses to complex eukaryotes.
• Comparative genomics: Understanding evolutionary relationships and genomic adaptations.
• Improving existing genomes: Closing gaps, correcting errors, and resolving complex regions in currently available reference genomes.
• Conservation biology: Providing genomic resources for endangered species.
• Agricultural research: Sequencing new crop varieties or livestock breeds to identify genes for desirable traits.

De Novo DNA Sequencing

While often synonymous with genome sequencing, de novo DNA sequencing can also refer to sequencing smaller, specific DNA molecules where a reference is absent. Examples include:

• Plasmid sequencing: Identifying novel plasmids in bacteria.
• Viral genome sequencing: Characterizing new or rapidly evolving viruses.
• Amplicon sequencing (without reference): Sequencing PCR products from unknown targets or highly variable regions.
• Mitochondrial or chloroplast genome sequencing: For phylogenetic studies or species identification.

De Novo Shotgun Sequencing

This is the predominant strategy for de novo genome sequencing. It involves:

1. Randomly shearing the genomic DNA into numerous small fragments.
2. Sequencing these fragments (often from both ends – "paired-end reads") to generate a large dataset of reads.
3. Using computational algorithms to identify overlapping reads and assemble them into longer contiguous sequences (contigs), and subsequently into scaffolds (ordered and oriented contigs).

The advent of long-read sequencing technologies has significantly enhanced de novo shotgun sequencing, particularly for resolving repetitive regions and complex structural variations that are challenging for short-read technologies alone.

De Novo Proteomics Sequencing

In proteomics, de novo sequencing refers to determining the amino acid sequence of a protein or peptide directly from its experimental mass spectrometry data, without relying on sequence databases.

De NovoProtein Sequencing

This is crucial for:

• Characterizing novel proteins: Proteins for which no gene or protein sequence is known.
• Analyzing proteins from organisms with unsequenced genomes.
• Identifying unexpected post-translational modifications (PTMs): As database searches might miss them if they are not pre-defined.
• Validating protein sequences derived from translated genomic data.
• Quality control of recombinant proteins: Verifying the sequence of manufactured biotherapeutics.

De Novo Peptide Sequencing

This is the core technique underlying de novo protein sequencing using mass spectrometry. Peptides (generated by enzymatic digestion of proteins, e.g., with trypsin) are ionized and subjected to tandem mass spectrometry (MS/MS). In an MS/MS experiment:

1. A precursor peptide ion is selected.
2. It is fragmented through collision-induced dissociation (CID), higher-energy collisional dissociation (HCD), electron-transfer dissociation (ETD), or other methods.
3. The m/z ratios of the resulting fragment ions (typically b-ions and y-ions) are measured.
4. The mass differences between adjacent fragment ions in a series correspond to the masses of individual amino acids, allowing the peptide sequence to be deduced.

Specialized algorithms are used to interpret these complex spectra and derive peptide sequences.

De Novo Antibody Sequencing

A specialized and highly significant application within proteomics, de novo antibody sequencing is vital for the development and characterization of therapeutic antibodies and for immunological research. Given the hypervariable nature of antibody complementarity-determining regions (CDRs), de novo approaches are often essential. Creative Biolabs excels in this area, offering robust de novo antibody sequencing services for:

• Monoclonal antibody discovery and development: Determining the sequence of promising hybridoma-derived antibodies.
• Intellectual property protection: Securing sequence information for novel antibodies.
• Antibody engineering: Providing the sequence template for humanization, affinity maturation, or other modifications.
• Understanding immune responses: Sequencing antibodies directly from B-cells.

Fig. 1 MS-based de novo sequencing solution of monoclonal antibodies.¹

Creative Biolabs' proprietary methodologies combine advanced mass spectrometry with sophisticated bioinformatics to deliver high-accuracy, full-length (variable and constant regions) antibody sequences, including the correct pairing of heavy and light chains.

De Novo Transcriptomics Sequencing

De novo transcriptome sequencing (RNA-Seq without a reference genome) allows for the assembly and analysis of the complete set of transcripts in a cell or tissue at a specific developmental stage or condition, without prior genomic information. Key applications include:

• Gene discovery in non-model organisms: Identifying protein-coding genes and non-coding RNAs.
• Alternative splicing analysis: Discovering novel transcript isoforms.
• Annotation of newly sequenced genomes: Providing experimental evidence for gene structures.
• Understanding gene expression in uncharacterized species.
• Identifying fusion transcripts or other structural RNA variations.

Similar to genome assembly, transcriptome assembly from short reads can be challenging due to alternative splicing and varying expression levels. Long-read sequencing is also increasingly applied to obtain full-length transcript isoforms.

Other Emerging Applications of De Novo Sequencing

De novosequencing continues to find new applications:

• Metagenomics: De novo assembly of genomes from mixed microbial communities allows for the characterization of unculturable microorganisms and their functional potential.
• Viromics: Discovering and characterizing novel viruses from environmental or clinical samples.
• Synthetic Biology: Verifying the sequences of custom-designed DNA constructs and synthetic organisms.
• Epigenomics (with a twist): While most epigenomic analyses rely on a reference, techniques like bisulfite sequencing can be performed, and the resulting modified sequences can be assembled de novo in simpler systems or to identify large-scale methylation patterns in the absence of a reference for context.

Methods and Technologies in De Novo Sequencing

The success of de novo sequencing hinges on sophisticated instrumentation and analytical techniques. The choice of technology depends on the type of molecule (DNA, RNA, or protein), the size and complexity of the target sequence, and the specific research goals.

Mass Spectrometry in De Novo Sequencing

Mass spectrometry (MS) is the cornerstone technology for de novo protein and peptide sequencing. It measures the mass-to-charge ratio (m/z) of ionized molecules, allowing for precise mass determination and structural elucidation.

• De Novo Sequencing using Mass Spectrometry (General)

In a typical proteomics workflow, proteins are first digested into peptides using enzymes like trypsin. These peptides are then separated (e.g., by liquid chromatography, LC) and introduced into the mass spectrometer. For de novo sequencing, tandem mass spectrometry is essential. A specific peptide ion (precursor ion) is selected in the first mass analyzer (MS1), fragmented, and the fragment ions (product ions) are analyzed in the second mass analyzer (MS2). The resulting MS/MS spectrum contains information about the masses of the amino acids in the peptide.

• De Novo Sequencing by ESI-MS/MS

Electrospray Ionization (ESI) is a soft ionization technique commonly coupled with MS for analyzing biomolecules, including peptides and proteins. ESI generates gas-phase ions from analytes in solution with minimal fragmentation, often producing multiply charged ions. This allows larger molecules like peptides to be analyzed within the m/z range of common mass analyzers. When coupled with tandem MS (ESI-MS/MS), it provides a powerful platform for de novo peptide sequencing.

• De Novo Sequencing using MS/MS

As mentioned, MS/MS is the key. The process involves:

• Ion Selection: Isolating a peptide precursor ion of a specific m/z.
• Fragmentation: Inducing fragmentation of the selected precursor ion.
• Fragment Ion Analysis: Measuring the m/z values of the product ions. The mass differences between ions in a series reveal the sequence of amino acids.

• Methods in Proteomics

The choice of fragmentation method and mass analyzer impacts the quality of data for de novo sequencing:

• High-resolution, high-accuracy mass analyzers are preferred as they allow for more confident determination of fragment ion masses and thus amino acid compositions.
• Combining fragmentation methods (e.g., CID and ETD) can provide complementary information, improving sequence coverage and confidence.
• Advanced algorithms are required to interpret complex MS/MS spectra, especially when dealing with mixed spectra, unexpected modifications, or non-canonical amino acids.

At Creative Biolabs, our state-of-the-art mass spectrometry facility is equipped with a suite of instruments capable of various fragmentation techniques, coupled with advanced bioinformatic pipelines for high-confidence de novo peptide and antibody sequencing.

Next-Generation Sequencing (NGS) for Nucleic Acids

NGS technologies, also known as high-throughput sequencing, have revolutionized de novo sequencing of DNA and RNA. They generate millions to billions of short sequence reads (typically 50-300 base pairs). The main challenge with short-read de novo assembly is resolving repetitive sequences longer than the read length and spanning large gaps. Paired-end or mate-pair libraries (sequencing both ends of larger DNA fragments) help to bridge gaps and order contigs into scaffolds.

Third-Generation Sequencing Technologies

Often referred to as long-read sequencing, these technologies offer significantly longer read lengths (kilobases to megabases), which are a major advantage for de novo assembly. Hybrid assembly approaches, combining the accuracy of short reads with the length of long reads, are also popular strategies to achieve high-quality de novo assemblies.

At Creative Biolabs, we combine decades of experience with cutting-edge technologies and a dedicated team of experts to provide comprehensive de novo sequencing services. We offer de novo antibody sequencing and de novo protein sequencing services, powered by our propriety DASS (Database Assisted Shotgun Sequencing) technology to meet the diverse protein research needs of our clients, driving innovation and advancement in the field of biomedical science.

Learn more about Creative Biolabs' de novo antibody sequencing services:

• De Novo Sequencing Services
• De Novo Human/Humanized Antibody Sequencing Service
• De Novo Biosimilar Monoclonal Antibody Sequencing Service
• De Novo Single Domain Antibody (SdAb) Sequencing Service
• De Novo Rodent Antibody Sequencing Service
• De Novo Rabbit Antibody Sequencing Service
• De Novo Chicken IgY Sequencing Service
• De Novo T Cell Receptor (TCR) Sequencing Service
• Hybridoma Sequencing Service

Loading case studies...

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.